Frontiers in Neuroscience
No selective OX1R agonist have been discovered to date.
The unique AEX platform consist of several highly selective Dual Orexin Receptor (OXR1/OXR2) Agonists compounds.
Previous finding suggest possible therapeutic targets for rare neurodegenerative diseases (HD, AD, KLS). Identification of neurological therapeutic targets are based on novel mechanistic approaches.
For potential treatment of Neurological Diseases.
Neurodegenerative disorders, which are defined by the breakdown of neurons over time, are affecting an increasing number of people. Stroke, Alzheimer’s, Parkinson’s, Multiple Sclerosis, Migraine, and Amyotrophic Lateral Sclerosis are just a few examples of brain disorders that have no cure. Besides, there is a huge demand for drugs that can cure the diseases mentioned above because the majority of the medications we use to treat them only alleviate diseases.
Discovery of Orexins System: Novel Neuropharmacology Perspectives
Narcolepsy Type 1 NT1
A rare neurological condition that affects the brain’s ability to regulate the normal sleep-wake cycle
Caused by a profound loss of orexin neurons in the brain
High Unmet Need
Current treatments do not restore normal function, and NT1 symptoms persist despite polypharmacy
- 75% patients experience EDS
- 50% patients still have 1-2 cataplexy episodes per day
Medicinal Chemistry & Intellectual Property
Medicinal Chemistry
AEX compounds are innovatively designed to be the best in class clinical candidate
Innovative aromatic heterocyclic compounds
Favorable physicochemical and biopharmaceutical properties
- Lipinski’s rule of five true
- Lipophilicity properties and values assessed (HBL, logP)
- Solubility pH 0 to pH 13 (0.0001 mg/ml)
- Pka, pH 0 to pH 9 (microspecies ⧣1, 100%; microspecies ⧣ 2, 0%)
Intellectual Property
Patent is filed (e.g. in narcolepsy, sleep disosders and various neurodegenerative disorders) in an international PCT (submitted: 30/12/2022)
The Company
Neurodegenerative disorders, defined by the breakdown of neurons over time, are affecting an increasing number of people.
Alzheimer’s, Parkinson’s, Huntington’s, Narcolepsy and Amyotrophic Lateral Sclerosis are just a few examples of brain disorders that have no cure. Current treatments do not address the route cause of the disorder and often lack therapeutical effectiveness and safety for these neurological disorders. That’s why the unmet medical need remains high in CNS in general.
Aexon Labs is conducting leading edge research on new compounds to address such unmet needs.
Aexon Labs Founder
Eric Konofal, MD, PhD
A drug-hunter and co-founder of NLS Pharmaceutics Inc. (NASDAQ: NLSP) a public company focusing on the treatment of rare CNS disorders.
He has a deep knowledge and expertise in clinical and scientific research and is a senior medical consultant for the Pediatric Sleep Disorders Center at the Robert-Debre University
of Paris (APHP) and served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University of Paris.
Dr. Konofal has been named (co-)author in over 76 peer-reviewed publications and is the inventor of over 88 patents world-wide.
Contact:
Email: ek@aexonlabs.com
Address
Aexon Labs. Inc
16192 Coastal Hwy
Lewes 19958, DE
USA
ek@aexonlabs.com